Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Cited by (1,013)

Items 101–200 of 1,013

1. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
   María‐Victoria Mateos, Andrew G Spencer, Ajay K. Nooka et al. · 2019 · Haematologica
2. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
   Niccolò Bolli, Elisa Genuardi, Bachisio Ziccheddu, Marina Martello, Stefania Oliva, Carolina Terragna · 2020 · Frontiers in Oncology
3. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
   Kari Hemminki, Asta Försti, Richard S. Houlston, Amit Sud · 2021 · International Journal of Cancer
4. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
   Robert J. Cronk, Joanna C. Zurko, Nirav Niranjan Shah · 2020 · Cancers
5. The emerging therapeutic landscape of relapsed/refractory multiple myeloma
   Benjamin Tanenbaum, Timothy Miett, Shyam Ajay Patel · 2022 · Annals of Hematology
6. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration
   Christian M. Schürch, Leo Rasche, Leonie Frauenfeld, Niels Weinhold, Falko Fend · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
7. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
   Renato Zambello, Gregorio Barilà, Sabrina Manni, Francesco Piazza, Gianpietro Semenzato · 2020 · Cells
8. CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
   Federica Costa, Benedetta Dalla Palma, Nicola Giuliani · 2019 · Cells
9. Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma
   Na Yu, Yifan Zhang, Jiaying Li, Wenxing Gu, Shujing Yue, Bin Li, Fenghua Meng, Huanli Sun, Rainer Haag, Jiandong Yuan et al. · 2021 · Advanced Materials
10. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
    Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew et al. · 2022 · The Lancet Haematology
11. How I treat relapsed multiple myeloma
    Efstathios Kastritis, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2022 · Blood
12. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
    Meletios Athanasios Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris S. Symeonidis, Jelena Bila et al. · 2023 · The Lancet Haematology
13. Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
    Francesca Bonello, Roberto Mina, Mario Boccadoro, Francesca Gay · 2019 · Cancers
14. Daratumumab in untreated newly diagnosed multiple myeloma
    Nadine H. Abdallah, Shaji Kunnathu Kumar · 2019 · Therapeutic Advances in Hematology
15. Targeting the Microenvironment for Treating Multiple Myeloma
    Peter Neumeister, Eduard Schulz, Katrin Pansy, Marta Szmyra, Alexander J. A. Deutsch · 2022 · International Journal of Molecular Sciences
16. Kidney injury and disease in patients with haematological malignancies
    Frank Bridoux, Paul Cockwell, Ilya G. Glezerman, Victoria Gutgarts, Jonathan J. Hogan, Kenar D. Jhaveri, Florent Joly, Samih H. Nasr, Deirdre L. Sawinski, Nelson Leung · 2021 · Nature Reviews Nephrology
17. Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
    Qian Shi, Bruno Paiva, Levi Pederson, Natalie Dimier, Ela Talpes, Thomas J. Prior, Alberto Órfão, Philippe Moreau, Pieter Sonneveld, Shaji Kunnathu Kumar et al. · 2025 · Journal of Clinical Oncology
18. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
    Sara Bringhen, Mattia D’Agostino, Laura París, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota‐Scalabrini, Luca De Rosa et al. · 2019 · Haematologica
19. Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
    Noémie Leblay, Ranjan Maity, Fajer Hasan, Paola E. Neri · 2020 · Frontiers in Oncology
20. Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
    Brian G.M. Durie, Shaji Kunnathu Kumar, Saad Z. Usmani, Bareng A. S. Nonyane, Eric M. Ammann, Annette Lam, Rachel Kobos, Eric M. Maiese, Thierry T.F. Facon · 2020 · American Journal of Hematology
21. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
    Jakub Radocha, Niels W.C.J. van de Donk, Katja Christina Weisel · 2021 · Cancers
22. Immunotherapy in Multiple Myeloma
    Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Sanjay De Mel, Wee Joo Chng · 2020 · Cells
23. How I treat high-risk multiple myeloma
    Elena Zamagni, Simona Barbato, Michèle Cavo · 2021 · Blood
24. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
    Matthew J. Rees, Mattia D’Agostino, Lisa Beatrice Leypoldt, Shaji Kunnathu Kumar, Katja Christina Weisel, Francesca Gay · 2024 · American Society of Clinical Oncology Educational Book
25. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
    Aurore Perrot, Thierry T.F. Facon, Torben Plesner, Saad Z. Usmani, Shaji Kunnathu Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Zygmunt Orlowski, Hareth Nahi, Peter N. Mollee et al. · 2020 · Journal of Clinical Oncology
26. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma
    Kishan Kamlesh Patel, Smith Giri, Terri L. Parker, Noffar Bar, Natalia Neparidze, Scott F. Huntington · 2021 · Journal of Clinical Oncology
27. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
    Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri · 2021 · Drug Design Development and Therapy
28. Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
    Stephanos Vassilopoulos, Athanasios Vassilopoulos, Markos Kalligeros, Fadi Shehadeh, Eleftherios E Mylonakis · 2022 · Open Forum Infectious Diseases
29. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
    Angelo Belotti, Rossella Ribolla, Valeria Cancelli, Claudia Crippa, Nicola Bianchetti, Samantha Ferrari, Chiara Bottelli, Chiara M. Cattaneo, Alessandra Tucci, Carmen De La Fuente Barrigon et al. · 2020 · American Journal of Hematology
30. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
    Nina D. Shah, Jack Aiello, David Avigan, Jesús G. Berdeja, Ivan Borrello, Ajai Chari, Adam D. Cohen, Karthik A. Ganapathi, Lissa Gray, Damian J. Green et al. · 2020 · Journal for ImmunoTherapy of Cancer
31. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2021 · Clinical Cancer Research
32. Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
    Arjun Lakshman, Shaji Kunnathu Kumar · 2021 · American Journal of Hematology
33. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
    Faith E. Davies, Charlotte Pawlyn, Saad Z. Usmani, Jesús F. San Miguel, Hermann Einsele, Eileen Mary Boyle, Jill Corre, Daniel Auclair, Hearn Jay Cho, Sagar Lonial et al. · 2022 · Blood Cancer Discovery
34. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
    Olivia Perez de Acha, Lauren T. Reiman, David S. Jayabalan, Zachary J. Walker, Grace Bosma, Alana L. Keller, Sarah E. Parzych, Diana Abbott, Beau M. Idler, Drew Ribadeneyra et al. · 2023 · Blood Advances
35. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy
    Steven Michael Bair, Joshua D. Brandstadter, Emily C. Ayers, Edward Allen Stadtmauer · 2020 · Cancer
36. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
    Shih‐Feng Cho, Lijie Xing, Kenneth Carl Anderson, Yu‐Tzu Tai · 2021 · Cancers
37. The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Maria Teresa Petrucci, Federico Vozella · 2019 · Cells
38. Recent Advances in the Treatment of Patients with Multiple Myeloma
    Mario Legarda, María José Cejalvo, Javier de la Rubia · 2020 · Cancers
39. Genome Instability in Multiple Myeloma: Facts and Factors
    Anna Yu. Aksenova, Anna S. Zhuk, Artem G. Lada, Irina V. Zotova, Elena Igorevna Stepchenkova, Ivan Ivanovich Kostroma, Sergey V. Gritsaev, Youri I. Pavlov · 2021 · Cancers
40. Role of minimal residual disease assessment in multiple myeloma
    Raphael Elie Szalat, Kenneth Carl Anderson, Nikhil C. Munshi · 2024 · Haematologica
41. Measurable residual disease in multiple myeloma: ready for clinical practice?
    Leire Burgos, Noemí Puig, María‐Teresa Cedena · 2020 · Journal of Hematology & Oncology
42. Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
    Charlotte Pawlyn, David Allan Cairns, Tom Menzies et al. · 2020 · Haematologica
43. Defining and Managing High-Risk Multiple Myeloma: Current Concepts
    Luciano J. Costa, Saad Z. Usmani · 2020 · Journal of the National Comprehensive Cancer Network
44. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
    Leona Yamamoto, Nicola Amodio, Annamaria Gullà, Kenneth Carl Anderson · 2021 · Frontiers in Oncology
45. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
    Jessica Caro, Marc Justin Braunstein, Louis S. Williams, Benedetto Bruno, David Kaminetzky, Ariel Siegel, Beatrice M. Razzo, Serge Alfandari, Gareth John Morgan, Faith E. Davies et al. · 2022 · Leukemia
46. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
    Jorge Julio Castillo, Natalie S. Callander, Muhamed Baljević, Douglas Weston Sborov, Shaji Kunnathu Kumar · 2021 · American Journal of Hematology
47. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
    Ashley Y. Choi, Miriam Manook, Danae Olaso, Brian Ezekian, Jae Berm Park, Kyle Freischlag, Annette M. Jackson, Stuart J. Knechtle, Jean Kwun · 2021 · Frontiers in Immunology
48. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study
    Jin Lu, Weijun Fu, Wei Li, Jianda Hu, Gang An, Yafei Wang, Chengcheng Fu, Lijuan Chen, Jie Jin, Xinan Cen et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
49. Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations
    Joseph R Mikhael, Manisha Bhutani, Craig Emmitt Cole · 2022 · The American Journal of Medicine
50. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
    Monika Martha Engelhardt, Klaus Martin Kortüm, Hartmut Goldschmidt, Maximilian Merz · 2024 · Haematologica
51. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
    Paolo Milani, Francesca Fazio, Marco Basset et al. · 2020 · American Journal of Hematology
52. A comprehensive approach to therapy of haematological malignancies in older patients
    Raúl Córdoba, Toby Andrew Eyre, Heidi D. Klepin, Tanya Marya Wildes, Valentin Goede · 2021 · The Lancet Haematology
53. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
    Weijun Fu, Soo‐Mee Bang, Honghui Huang, Kihyun Kım, Wei Li, Gang An, Je‐Jung Lee, Zhen Cai, Jie Jin, Yafei Wang et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
54. Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
    Mattia D’Agostino, Luca Bertamini, Stefania Oliva, Mario Boccadoro, Francesca Gay · 2019 · Cancers
55. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
    Matthew Ho, Chia Yin Goh, Ashish S Patel, Susannah Staunton, Ronan O’Connor, Marc Godeau, Giada Bianchi · 2020 · Clinical Lymphoma Myeloma & Leukemia
56. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
    Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Saida Absalah, Patricia W. C. Maas-Bosman, Sandy Kruyswijk, Inger S. Nijhof, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk · 2020 · Oncotarget
57. Advances in Management for Older Adults With Hematologic Malignancies
    Ashley Elizabeth Rosko, Raúl Córdoba, Gregory Alan Abel, Andrew S. Artz, Kah Poh Loh, Heidi D. Klepin · 2021 · Journal of Clinical Oncology
58. Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019
    Shaji Kunnathu Kumar, Mellissa Williamson, Uzor C. Ogbu, Andy Surinach, Stella Arndorfer, Wan‐Jen Hong · 2021 · Cancer Medicine
59. Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampos M. Charalampous, Taxiarchis Kourelis · 2022 · Frontiers in Oncology
60. Treatment horizon in multiple myeloma
    Cinnie Yentia Soekojo, Wee Joo Chng · 2022 · European Journal Of Haematology
61. What is the future of immunotherapy in multiple myeloma?
    Leo Rasche, Michael Hudecek, Hermann Einsele · 2020 · Blood
62. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab
    Kyeongmin Kim, Mitch A. Phelps · 2023 · Clinical Pharmacokinetics
63. The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
    Eleonora Calabretta, Carmelo Carlo‐Stella · 2020 · Cells
64. Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
    Christie P.M. Verkleij, Amy Jhatakia, Marloes E.C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie Bezman, Niels W.C.J. van de Donk · 2020 · Cancers
65. Harnessing natural killer cells for the treatment of multiple myeloma
    Joseph Clara, Richard W. Childs · 2022 · Seminars in Oncology
66. Targeting CD38 in Neoplasms and Non-Cancer Diseases
    Wojciech Szlasa, Jakub Czarny, Natalia Julia Sauer, Katarzyna Rakoczy, Natalia Szymańska, Jakub Stecko, Maksymilian Kołodziej, Maciej Kaźmierczak, Ewa Barg · 2022 · Cancers
67. Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
    Arthur Bobin, Évelyne Liuu, Niels Moya, Cécile Gruchet, Florence Sabirou, Anthony Lévy, Hélène Gardeney, Laly Nsiala, Laura Cailly, Stéphanie Guidez et al. · 2020 · Cancers
68. Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
    Natasha Mupeta Kaweme, Geoffrey Joseph Changwe, Fuling Zhou · 2021 · Frontiers in Medicine
69. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
    Jill Corre, Aurore Perrot, Cyrille Hulin, Denis Caillot, Anne‐Marie Stoppa, Thierry T.F. Facon, Xavier P Leleu, Mamoun Dib, Lionel Karlin, Philippe Moreau et al. · 2021 · Leukemia
70. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
    Matthew Ho, Alexander H. Xiao, Dongni Yi, Saurabh Zanwar, Giada Bianchi · 2022 · Current Oncology
71. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
    Danilo De Novellis, Raffaele Fontana, Valentina Giudice, Bianca Serio, Carmine Selleri · 2022 · International Journal of Molecular Sciences
72. Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
    Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou et al. · 2020 · HemaSphere
73. Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
    Lip Leong Chong, Yu Yang Soon, Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Wee Joo Chng, Sanjay De Mel · 2020 · Critical Reviews in Oncology/Hematology
74. High-risk multiple myeloma: how to treat at diagnosis and relapse?
    María‐Victoria Mateos, Borja Puertas, Verónica González‐Calle · 2021 · Hematology
75. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
    Thierry T.F. Facon, Jesús F. San Miguel, Meletios Athanasios Dimopoulos et al. · 2022 · Advances in Therapy
76. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
    Christos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou‐Strauss · 2019 · Molecules
77. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Maximilian Merz, Tobias Nicolaas Dechow, Mithun Scheytt, Christian Schmidt, Bjoern Hackanson, Stefan Tobias Knop · 2020 · Annals of Hematology
78. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
    Saad Z. Usmani, María‐Victoria Mateos, Vânia Hungria, Shinsuke Iida, Nizar Jacques Bahlis, Hareth Nahi, Hila Magen, Michèle Cavo, Cyrille Hulin, Darrell J. White et al. · 2020 · Journal of Cancer Research and Clinical Oncology
79. Facts and Hopes in Multiple Myeloma Immunotherapy
    Adam Samuel Sperling, Kenneth Carl Anderson · 2021 · Clinical Cancer Research
80. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
    Andrzej J. Jakubowiak, Shaji Kunnathu Kumar, Rohan Medhekar et al. · 2022 · The Oncologist
81. The Effect of STEM (Science, Technology, Engineering, and Mathematics) Based Learning Approach on Critical Thinking Skills and Cognitive Learning Outcomes of Class X SMA Negeri 1
    Ipah Budi Minarti, Muhammad Anas Dzakiy, Dila Nilautama · 2023 · At-Tasyrih jurnal pendidikan dan hukum Islam
82. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
    Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law · 2023 · World Journal of Gastroenterology
83. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
    Limei Xu, Caining Wen, Jiang Xia, Hao Zhang, Yujie Liang, Xiao Gang Xu · 2024 · Cell Death Discovery
84. Checklist for clinical applicability of subgroup analysis
    Manuel David Gil‐Sierra, Silvia Fenix-Caballero, Laila Abdel‐Kader Martín, Maria Dolores Fraga‐Fuentes, Marina Sánchéz‐Hidalgo, Catalina Alarcón de la Lastra‐Romero, Emilio Jesús Alegre Del Rey · 2019 · Journal of Clinical Pharmacy and Therapeutics
85. Current approaches to management of high‐risk multiple myeloma
    Sarah Goldman‐Mazur, Shaji Kunnathu Kumar · 2021 · American Journal of Hematology
86. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis
    Szabolcs Kiss, Noémi Gede, Alexandra Soós, Péter Jenő Hegyi, Bettina Nagy, Marcell Imrei, Bernadett Czibere, Nelli Farkas, Lilla Hanák, Zsolt Szakács et al. · 2021 · Critical Reviews in Oncology/Hematology
87. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
    Luca Bertamini, Giuseppe Bertuglia, Stefania Oliva · 2022 · Frontiers in Oncology
88. Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
    Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hébraud, Cyrille Hulin, Marie C. Béné, Annemiek Broijl, Denis Caillot, Michel Delforge, Thomas Dejoie et al. · 2025 · Blood
89. How I treat triple‐class refractory multiple myeloma
    Luciano J. Costa, Vânia Hungria, Mohamad Mohty, María‐Victoria Mateos · 2022 · British Journal of Haematology
90. Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
    Kari Lenita Falck Moore, Ingemar Turesson, Anna Genell, Tobias Wirenfeldt Klausen, Dorota Knut‐Bojanowska, Louise Redder, Ingigerdur Solveig Sverrisdottir, Jonathan Thorsen, Annette Juul Vangsted, Cecilie Hveding Blimark · 2022 · Haematologica
91. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
    Danai Dima, Fauzia Ullah, Sandra Ann Mazzoni, Louis S. Williams, Beth M Faiman, Austin Kurkowski, Chakra P. Chaulagain, Shahzad Raza, Christy Joy Samaras, Jason Neil Valent et al. · 2023 · Cancers
92. Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
    Kerry A. Whalen, Kavya Rakhra, Naveen K. Mehta, Alexander Steinle, Jennifer S. Michaelson, Patrick A. Baeuerle · 2023 · mAbs
93. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
    Jasneet Kaur, Sai Sudha Valisekka, Maha Hameed, Pushyami Satya Bandi, Samyukta Varma, Chibuzor Joseph Onwughalu, Hany Ibrahim, Himani Mongia · 2023 · Clinical Lymphoma Myeloma & Leukemia
94. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
    Stefania Oliva, Elisa Genuardi, Laura París, Mattia D’Agostino, Jennifer Rogers, Delia Rota‐Scalabrini, Allison P. Jacob, Francesca F. Patriarca, Mario Luppi, Paola Bertazzoni et al. · 2023 · EClinicalMedicine
95. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
    Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin T. Diamond, Paolo Corradini et al. · 2024 · Blood Cancer Journal
96. Endothelial Progenitors in the Tumor Microenvironment
    Ugo Testa, Elvira Pelosi, Germana Castelli · 2020 · Advances in experimental medicine and biology
97. Use of daratumumab in high risk multiple myeloma: A meta‐analysis
    Vikram J. Premkumar, Samuel M Pan, Suzanne Lentzsch, Divaya Bhutani · 2020 · eJHaem
98. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
    Noemí Puig, Miguel T. Hernández, Laura Rosiñol, Esther González, Felipe de Arriba, Albert Oriol, Verónica González‐Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella et al. · 2021 · Blood Cancer Journal
99. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
    Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih‐Feng Cho et al. · 2021 · Clinical Cancer Research
100. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
     Grzegorz Charliński, David H. Vesole, Artur J. Jurczyszyn · 2021 · Cancers